Pharma IQ Glossary: Active Pharmaceutical Ingredient
Active Pharmaceutical Ingredient (API) is any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.
Pharmaceutical Serialisation and Traceability 2012
July 23 by Pharma IQ SurveysCreate your free online surveys with SurveyMonkey, the world's leading questionnaire tool. [inlinead] Pharma-IQ.com in conjunction with Pharmaceutical Serialisation and Traceability Summit 2012...
Best Conference Tips: How to Choose the Right Conference or Platform to Win New Business
June 16 by Andrea CharlesChoosing the right platform or conference to showcase your product and services to potential clients in the pharma space can be a challenge for those working in business development, sales and ma...
What if the Medication that was Supposed to Keep you Alive was Actually Killing You?
June 15 by Pharma IQ NewsIn a chilling new book Roger Bate blows the whistle on what could be America’s greatest health crisis. “Phake: The Deadly World of Falsified and Substandard Medicines” reveals how ruthless criminals p...
IN PROFILE: 2011 Top 10 Players in the Japanese Pharmaceutical Market
June 29 by Pharma IQPharma IQ provides you with a quick update of the activities of the Top 10 players in the Japanese pharmaceutical market in 2011. Figures according to Forbes The World Bi...
DIA Presents 10 Global Awards
June 19 by Andrea CharlesThe DIA Global Award winners were announced this morning at the opening plenary session of DIA 2011. Recognised for a range of achievements the winners were:Distinguished Career Award...
The Rise of Academic/Industry Collaboration in Amorphous Material Studies
May 30 by Helen WinsorMarc Descamps, Professor in Solid State Physics at Université Lille and Lead of the European ID Network for Improved Drug Efficacy and Availability, joins Helen Winsor from Pharma IQ, to discuss the u...
Cost Savings Still the Number One Reason Behind 60% of Outsourced Pharma and Bio Manufacturing
May 15 by Pharma IQWhile there is normally more than one factor behind the decision of a pharmaceutical or biopharmaceutical organisation to outsource its global manufacturing, it seems the ever-important cost-saving po...
Don’t Get Lost in Translation – Reflections on Pharmaceutical Labelling
May 07 by Helen WinsorMark Gibson, Consumer Information Specialist at Gibson Research Consultancy, joins Helen Winsor form Pharma IQ, to discuss packaging and labelling in the healthcare industry. In this exclusive intervi...
Pharmaceutical Revenues under Threat - The Impact of Expected Major Changes and New Regulations
March 25 by Cristina FalcãoBased on new regulations, increased costs of R & D, the expiration of dozens of patents, the lack of future ‘cash cows’, the new transparency rules and the value-based pricing, pharmaceutical comp...
Are Pharmaceutical Supply Chains Due an Outsourcing Overhaul?
March 10 by Pharma IQThe current manufacturing and distribution infrastructure of drugmakers across the globe may be uanble to cope with the future challenges facing pharmaceuticals worldwide. Research publishe...
Hear How You Can Successfully Manage The Complexities Of Demand Planning On A Global Scale at Pharma IQ’s Global Strategic Pharmaceutical Demand Planning, Amsterdam, 24th - 26th May
March 08 by Pharma IQ NewsDemand planning in turbulent market conditions is challenging, doing it while other people are throwing different figures at you is even worse, and getting the forecast 100% correct is impossible – so...
Middle East North Africa Pharmaceutical Market - In Transition
September 12 by Aparna Krishnan
The Middle East and the North Africa (MENA) region constitute just 2 percent of global pharmaceutical sales. A rapid increase in population has stoked drug demand especially for higher-yield pharmaceu...
